Could a drug plus light therapy reverse vitiligo? new trial tests the combo
NCT ID NCT04822584
First seen May 16, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This phase 2 trial tested whether adding the oral drug baricitinib to phototherapy (light treatment) helps restore skin color in adults with progressive vitiligo. 49 participants received either baricitinib plus phototherapy or a placebo plus phototherapy for 36 weeks. The main goal was to measure changes in the amount of skin affected by vitiligo using the VASI score.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VITILIGO are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Hospitalier Universitaire de Nice - Service de Dermatologie
Nice, 06000, France
-
Service de Dermatologie - Hôpital Saint-André
Bordeaux, Bordeaux, 33075, France
-
Service de dermatologie - Hôpital Henri Mondor - EA EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques)
Créteil, 94010, France
-
Service de dermatologie Centre de Référence des Maladies Rares de la Peau et des muqueuses d'origine génétique - Hôpital Larrey
Toulouse, 31059 cedex 9, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Baricitinib (an oral drug that calms the immune system) plus phototherapy (light treatment)
What this could lead to
If it works, this could point toward a new treatment option that helps restore skin color in people with progressive vitiligo.
What could go wrong
This is a small, early-phase study (49 people) with no comparison to a standard treatment group. Results may not apply to everyone, and baricitinib can have side effects like infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.